ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter
- First Posted Date
- 2005-06-27
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 276
- Registration Number
- NCT00115791
- Locations
- 🇸🇪
Investigative Site, Uppsala, Sweden
Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients
Phase 4
Completed
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2005-06-08
- Last Posted Date
- 2011-08-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 501
- Registration Number
- NCT00113269
A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis
Phase 4
Completed
- Conditions
- Dermatitis, Atopic
- Interventions
- First Posted Date
- 2005-03-28
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 410
- Registration Number
- NCT00106496
- Locations
- 🇺🇸
Investigational Site, Dallas, Texas, United States
A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
Phase 4
Completed
- Conditions
- Erectile DysfunctionProstate Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-03-24
- Last Posted Date
- 2010-11-23
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 131
- Registration Number
- NCT00106392
Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia
- First Posted Date
- 2005-03-23
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 637
- Registration Number
- NCT00106288
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
- First Posted Date
- 2005-03-08
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 611
- Registration Number
- NCT00105144
Study of FK778 in Renal Transplant Recipients With Untreated BK Nephropathy
Phase 2
Terminated
- Conditions
- BK PolyomavirusKidney Diseases
- First Posted Date
- 2005-02-25
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 45
- Registration Number
- NCT00104338
YM443 in Subjects With Functional Dyspepsia
Phase 2
Completed
- Conditions
- NauseaIndigestion
- First Posted Date
- 2005-01-27
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 416
- Registration Number
- NCT00102310
- Locations
- 🇺🇸
Dr. Michael Bennett, San Diego, California, United States
🇺🇸Dr. William Snape, San Francisco, California, United States
🇺🇸Dr. Braden Kuo, Boston, Massachusetts, United States
A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease
Phase 2
Terminated
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 510
- Registration Number
- NCT00087724
- Locations
- 🇺🇸
Investigative Site, Denver, Colorado, United States
🇨🇦Investigational Site, Regina, Saskatchewan, Canada
A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients
Phase 3
Completed
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2004-06-17
- Last Posted Date
- 2011-10-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 600
- Registration Number
- NCT00085826
- Locations
- 🇺🇸
Oncology-Hematology Associates, Pittsburgh, Pennsylvania, United States
🇺🇸Temple Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸The Texas Cancer Center - Dallas Southwest, Dallas, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath